1. Home
  2. SSP vs CBIO Comparison

SSP vs CBIO Comparison

Compare SSP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$3.80

Market Cap

341.0M

Sector

Industrials

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$19.41

Market Cap

340.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSP
CBIO
Founded
1878
2003
Country
United States
United States
Employees
N/A
44
Industry
Broadcasting
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
341.0M
340.4M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
SSP
CBIO
Price
$3.80
$19.41
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$6.95
$26.67
AVG Volume (30 Days)
709.7K
219.7K
Earning Date
05-07-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,150,585,000.00
N/A
Revenue This Year
$8.34
N/A
Revenue Next Year
N/A
$355.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$8.72
52 Week High
$4.98
$20.58

Technical Indicators

Market Signals
Indicator
SSP
CBIO
Relative Strength Index (RSI) 51.10 78.57
Support Level $3.21 $10.89
Resistance Level $3.92 N/A
Average True Range (ATR) 0.25 1.57
MACD 0.01 0.80
Stochastic Oscillator 82.44 86.00

Price Performance

Historical Comparison
SSP
CBIO

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: